Mozavaptan-d6

Mozavaptan-d6 is intended for use as an internal standard for the quantification of mozavaptan (Cay-16664) by GC- or LC-MS. Mozavaptan is an orally bioavailable antagonist of vasopressin V2 receptors (Ki = 9.42 nM in HeLa cells expressing the human receptor). It is selective for vasopressin V2 over V1 receptors (IC50s = 14 and 1,200 nM, respectively) in radioligand binding assays using rat kidney and rat liver membranes that endogenously express high levels of vasopressin V2 and V1 receptors, respectively. Mozavaptan (10-30 mg/kg, p.o.) increases urine volume and decreases urine osmolality, indicating aquaresis, in conscious rats. It reduces decreases in urine flow and increases in urine osmolality induced by arginine vasopressin (AVP, Cay-24154) in anesthetized rats when administered intravenously at doses ranging from 10 to 100 µg/kg.Formal Name: N-[4-[[5-(dimethyl-d6-amino)-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]carbonyl]phenyl]-2-methyl-benzamide. CAS Number: 2750534-83-7. Molecular Formula: C27H23D6N3O2. Formula Weight: 433.6. Purity: >99% deuterated forms (d1-d6). Formulation: (Request formulation change), A solid. Solubility: Acetonitrile:Methanol (1:1): Soluble, DMF: Soluble, DMSO: Soluble. SMILES: CC1=CC=CC=C1C(NC2=CC=C(C(N3C(C=CC=C4)=C4C(N(C([2H])([2H])[2H])C([2H])([2H])[2H])CCC3)=O)C=C2)=O. InChi Code: InChI=1S/C27H29N3O2/c1-19-9-4-5-10-22(19)26(31)28-21-16-14-20(15-17-21)27(32)30-18-8-13-24(29(2)3)23-11-6-7-12-25(23)30/h4-7,9-12,14-17,24H,8,13,18H2,1-3H3,(H,28,31)/i2D3,3D3. InChi Key: WRNXUQJJCIZICJ-XERRXZQWSA-N.